07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Aeterna Zentaris deal

Aeterna Zentaris granted an undisclosed, privately held German life sciences company a 12-month option to license exclusive, worldwide rights to develop and commercialize Aeterna’s live, recombinant, oral, allogeneic tumor vaccine technology, including AEZS-120. Preclinical...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Aeterna Zentaris preclinical data

In mice, single and multiple doses of oral AEZS-120 each led to significant and comparable protection from challenge with a recombinant prostate-specific antigen ( KLK3; PSA) expressing tumor cell line. Aeterna Zentaris said that...